{"entity":{"type":"insider","cik":"0001423029","url":"/insider/0001423029","json_url":"/insider/0001423029.json","name":"Anzalone Christopher Richard","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":111,"n_filings":42,"first":"2008-08-25","last":"2026-01-05","span_basis":"filed_date"},"name_variants":[{"name":"Anzalone Christopher Richard","source":"filing","n_filings":42,"first_seen":"2008-08-25","last_seen":"2026-01-05"}],"transactions":[{"id":6008763,"accession":"0001423029-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001423029-26-000001","line_url":"/filing/0001423029-26-000001","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13187.0,"shares_display":"13,187","price_per_share":66.10319026313793,"price_display":"66.10","price_state":"stated","total_value":871702.77,"total_display":"871,702.77","total_whole":"871,703","shares_owned_after":3798510.0,"shares_owned_after_display":"3,798,510","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-05","scope":"insider","n_lines":2},{"id":4359181,"accession":"0001423029-25-000009","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001423029-25-000009","line_url":"/filing/0001423029-25-000009","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51726.0,"shares_display":"51,726","price_per_share":69.1252905695395,"price_display":"69.13","price_state":"stated","total_value":3575574.78,"total_display":"3,575,574.78","total_whole":"3,575,575","shares_owned_after":3822471.0,"shares_owned_after_display":"3,822,471","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-29","filed_date":"2025-12-30","scope":"insider","n_lines":2},{"id":5155457,"accession":"0001423029-25-000007","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001423029-25-000007","line_url":"/filing/0001423029-25-000007","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12586.0,"shares_display":"12,586","price_per_share":68.43634673446687,"price_display":"68.44","price_state":"stated","total_value":861339.86,"total_display":"861,339.86","total_whole":"861,340","shares_owned_after":3808500.0,"shares_owned_after_display":"3,808,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-22","filed_date":"2025-12-23","scope":"insider","n_lines":2},{"id":5155445,"accession":"0001423029-25-000007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001423029-25-000007","line_url":"/filing/0001423029-25-000007","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13445.0,"shares_display":"13,445","price_per_share":67.65954034957232,"price_display":"67.66","price_state":"stated","total_value":909682.52,"total_display":"909,682.52","total_whole":"909,683","shares_owned_after":3819831.0,"shares_owned_after_display":"3,819,831","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-19","filed_date":"2025-12-23","scope":"insider","n_lines":3},{"id":4320881,"accession":"0001423029-25-000005","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001423029-25-000005","line_url":"/filing/0001423029-25-000005","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85000.0,"shares_display":"85,000","price_per_share":64.04073070588235,"price_display":"64.04","price_state":"stated","total_value":5443462.11,"total_display":"5,443,462.11","total_whole":"5,443,462","shares_owned_after":3870670.0,"shares_owned_after_display":"3,870,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-17","filed_date":"2025-12-19","scope":"insider","n_lines":4},{"id":4246414,"accession":"0001423029-25-000003","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001423029-25-000003","line_url":"/filing/0001423029-25-000003","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54298.0,"shares_display":"54,298","price_per_share":62.58400917160853,"price_display":"62.58","price_state":"stated","total_value":3398186.53,"total_display":"3,398,186.53","total_whole":"3,398,187","shares_owned_after":3937781.0,"shares_owned_after_display":"3,937,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-16","filed_date":"2025-12-16","scope":"insider","n_lines":9},{"id":4246382,"accession":"0001423029-25-000003","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001423029-25-000003","line_url":"/filing/0001423029-25-000003","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":130000.0,"shares_display":"130,000","price_per_share":68.850888,"price_display":"68.85","price_state":"stated","total_value":8950615.44,"total_display":"8,950,615.44","total_whole":"8,950,615","shares_owned_after":4000723.0,"shares_owned_after_display":"4,000,723","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-16","scope":"insider","n_lines":3},{"id":4032872,"accession":"0001628280-25-017592","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001628280-25-017592","line_url":"/filing/0001628280-25-017592#line-5","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50800.0,"shares_display":"50,800","price_per_share":11.49,"price_display":"11.49","price_state":"stated","total_value":583692.0,"total_display":"583,692.00","total_whole":"583,692","shares_owned_after":3921255.0,"shares_owned_after_display":"3,921,255","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-11","filed_date":"2025-04-11","scope":"insider"},{"id":4032871,"accession":"0001628280-25-017592","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-25-017592","line_url":"/filing/0001628280-25-017592#line-4","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":10.87,"price_display":"10.87","price_state":"stated","total_value":543500.0,"total_display":"543,500.00","total_whole":"543,500","shares_owned_after":3972055.0,"shares_owned_after_display":"3,972,055","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-10","filed_date":"2025-04-11","scope":"insider"},{"id":4032869,"accession":"0001628280-25-017592","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001628280-25-017592","line_url":"/filing/0001628280-25-017592","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40322.0,"shares_display":"40,322","price_per_share":10.072530380437478,"price_display":"10.07","price_state":"stated","total_value":406144.57,"total_display":"406,144.57","total_whole":"406,145","shares_owned_after":4027072.0,"shares_owned_after_display":"4,027,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-09","filed_date":"2025-04-11","scope":"insider","n_lines":3},{"id":4071274,"accession":"0001628280-25-013210","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-25-013210","line_url":"/filing/0001628280-25-013210#line-2","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":51425.0,"shares_display":"51,425","price_per_share":15.07,"price_display":"15.07","price_state":"stated","total_value":774974.75,"total_display":"774,974.75","total_whole":"774,975","shares_owned_after":4062377.0,"shares_owned_after_display":"4,062,377","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-13","filed_date":"2025-03-17","scope":"insider"},{"id":5111048,"accession":"0001628280-25-010672","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-25-010672","line_url":"/filing/0001628280-25-010672#line-4","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":133333.0,"shares_display":"133,333","price_per_share":17.02,"price_display":"17.02","price_state":"stated","total_value":2269327.66,"total_display":"2,269,327.66","total_whole":"2,269,328","shares_owned_after":3773802.0,"shares_owned_after_display":"3,773,802","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-04","filed_date":"2025-03-05","scope":"insider"},{"id":5111039,"accession":"0001628280-25-010672","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-25-010672","line_url":"/filing/0001628280-25-010672#line-2","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":166667.0,"shares_display":"166,667","price_per_share":18.03,"price_display":"18.03","price_state":"stated","total_value":3005006.01,"total_display":"3,005,006.01","total_whole":"3,005,006","shares_owned_after":3907135.0,"shares_owned_after_display":"3,907,135","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-05","scope":"insider"},{"id":4385423,"accession":"0001628280-25-000673","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-25-000673","line_url":"/filing/0001628280-25-000673#line-1","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11520.0,"shares_display":"11,520","price_per_share":19.05,"price_display":"19.05","price_state":"stated","total_value":219456.0,"total_display":"219,456.00","total_whole":"219,456","shares_owned_after":3764252.0,"shares_owned_after_display":"3,764,252","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-02","filed_date":"2025-01-06","scope":"insider"},{"id":2830575,"accession":"0001628280-24-052347","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-24-052347","line_url":"/filing/0001628280-24-052347#line-1","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12563.0,"shares_display":"12,563","price_per_share":19.59,"price_display":"19.59","price_state":"stated","total_value":246109.17,"total_display":"246,109.17","total_whole":"246,109","shares_owned_after":3775772.0,"shares_owned_after_display":"3,775,772","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-23","scope":"insider"},{"id":2970651,"accession":"0001628280-24-052267","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001628280-24-052267","line_url":"/filing/0001628280-24-052267","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26712.0,"shares_display":"26,712","price_per_share":21.244603174603174,"price_display":"21.24","price_state":"stated","total_value":567485.84,"total_display":"567,485.84","total_whole":"567,486","shares_owned_after":3702394.0,"shares_owned_after_display":"3,702,394","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-18","filed_date":"2024-12-20","scope":"insider","n_lines":3},{"id":2829225,"accession":"0001628280-24-003097","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001628280-24-003097","line_url":"/filing/0001628280-24-003097","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57499.0,"shares_display":"57,499","price_per_share":32.348725021304716,"price_display":"32.35","price_state":"stated","total_value":1860019.34,"total_display":"1,860,019.34","total_whole":"1,860,019","shares_owned_after":3734778.0,"shares_owned_after_display":"3,734,778","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider","n_lines":2},{"id":2703526,"accession":"0001628280-24-000478","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-24-000478","line_url":"/filing/0001628280-24-000478","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9952.0,"shares_display":"9,952","price_per_share":31.01252612540193,"price_display":"31.01","price_state":"stated","total_value":308636.66,"total_display":"308,636.66","total_whole":"308,637","shares_owned_after":3715048.0,"shares_owned_after_display":"3,715,048","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider","n_lines":2},{"id":8211901,"accession":"0001628280-23-042646","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-042646","line_url":"/filing/0001628280-23-042646#line-1","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":28.54,"price_display":"28.54","price_state":"stated","total_value":342480.0,"total_display":"342,480.00","total_whole":"342,480","shares_owned_after":3725000.0,"shares_owned_after_display":"3,725,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-20","filed_date":"2023-12-22","scope":"insider"},{"id":8007754,"accession":"0001628280-23-035430","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-035430","line_url":"/filing/0001628280-23-035430#line-1","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24338.0,"shares_display":"24,338","price_per_share":24.21,"price_display":"24.21","price_state":"stated","total_value":589222.98,"total_display":"589,222.98","total_whole":"589,223","shares_owned_after":3737000.0,"shares_owned_after_display":"3,737,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-25","filed_date":"2023-10-27","scope":"insider"},{"id":8047602,"accession":"0001628280-23-032707","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001628280-23-032707","line_url":"/filing/0001628280-23-032707","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57755.0,"shares_display":"57,755","price_per_share":28.122632499350704,"price_display":"28.12","price_state":"stated","total_value":1624222.64,"total_display":"1,624,222.64","total_whole":"1,624,223","shares_owned_after":3787570.0,"shares_owned_after_display":"3,787,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-18","filed_date":"2023-09-20","scope":"insider","n_lines":2},{"id":8339788,"accession":"0001628280-23-016223","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001628280-23-016223","line_url":"/filing/0001628280-23-016223","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":39.515832,"price_display":"39.52","price_state":"stated","total_value":1975791.6,"total_display":"1,975,791.60","total_whole":"1,975,792","shares_owned_after":3761338.0,"shares_owned_after_display":"3,761,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-04","filed_date":"2023-05-05","scope":"insider","n_lines":2},{"id":8339774,"accession":"0001628280-23-016223","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-23-016223","line_url":"/filing/0001628280-23-016223#line-2","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54928.0,"shares_display":"54,928","price_per_share":39.14,"price_display":"39.14","price_state":"stated","total_value":2149881.92,"total_display":"2,149,881.92","total_whole":"2,149,882","shares_owned_after":3761338.0,"shares_owned_after_display":"3,761,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-03","filed_date":"2023-05-05","scope":"insider"},{"id":6889598,"accession":"0001209191-22-009052","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-22-009052","line_url":"/filing/0001209191-22-009052#line-5","is_derivative":false,"issuer_cik":"0000879407","issuer_name":"ARROWHEAD PHARMACEUTICALS, INC.","issuer_ticker":"ARWR","issuer_name_source":null,"issuer_url":"/issuer/0000879407","owner_cik":"0001423029","owner_name":"Anzalone Christopher Richard","owner_display_name":"Anzalone Christopher Richard","owner_url":"/insider/0001423029","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61482.0,"shares_display":"61,482","price_per_share":50.9,"price_display":"50.90","price_state":"stated","total_value":3129433.8,"total_display":"3,129,433.80","total_whole":"3,129,434","shares_owned_after":4059534.0,"shares_owned_after_display":"4,059,534","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-11","filed_date":"2022-02-14","scope":"insider"}],"collapsed":true,"next_cursor":"2022-02-11|6889598","ledger_fault":false,"count":{"value":111,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":5,"open_market":true},{"code":"S","label":"Open-market sale","n":106,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":111},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000879407","name":"ARROWHEAD PHARMACEUTICALS, INC.","url":"/issuer/0000879407","role":"Director, Officer (Chief Executive Officer)","n_filings":42,"first_seen":"2008-08-25","last_seen":"2026-01-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001423029","retrieved_at":"2026-08-23T19:02:56+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}